# Trontinemab

Source: https://onco.cc/drugs/da-trontinemab/  
OnCo record `da-trontinemab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Trontinemab is an investigational anti-amyloid antibody in Phase 3. It is not approved and is not for self-administration.

## Summary

Roche’s Brainshuttle programme aims to improve brain uptake. Phase 3 safety and benefit are still being established. A trial listing is not a recommendation to join a study.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Modality: mAb
- Mechanism: Investigational amyloid-directed antibody designed for enhanced brain delivery (Brainshuttle).

## Sources

- ClinicalTrials.gov NCT07170150: https://clinicaltrials.gov/study/NCT07170150

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/), [Mild cognitive impairment](https://onco.cc/diagnoses/mild-cognitive-impairment/)
- targets: [Amyloid-beta](https://onco.cc/targets/da-target-amyloid-beta/)
- companies: [Roche](https://onco.cc/companies/da-roche/)
- trials: [TRONTIER 2 (trontinemab Phase 3)](https://onco.cc/trials/da-trial-trontier/)

---
JSON: https://onco.cc/api/v1/entities/da-trontinemab.json